William A Hall1, Lauren E Colbert1, Dana Nickleach1, Jeffrey Switchenko1, Yuan Liu1, Theresa Gillespie1, Joseph Lipscomb1, Claire Hardy1, David A Kooby1, Roshan S Prabhu1, John Kauh1, Jerome C Landry1. 1. 1 Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA ; 2 Biostatistics & Bioinformatics Shared Resource at Winship Cancer Institute, Atlanta, GA, USA ; 3 Department of Surgery and Winship Cancer Institute, Emory University, Atlanta, GA, USA ; 4 Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA ; 5 Rollins School of Public Health and Winship Cancer Institute, Atlanta, GA, USA ; 6 Department of Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Abstract
PURPOSE: Radiation therapy (RT) dose escalation in unresectable pancreatic adenocarcinoma (PAC) remains investigational. We examined the association between total RT dose and overall survival (OS) in patients with unresectable PAC. METHODS AND MATERIALS: National cancer data base (NCDB) data were obtained for patients who underwent definitive chemotherapy and RT (chemo-RT) for unresectable PAC. Univariate (UV) and multivariate (MV) survival analysis were performed along with Kaplan-Meier (KM) estimates for incremental RT dose levels. RESULTS: A total of 977 analyzable patients met inclusion criteria. Median tumor size was 4.0 cm (0.3-40 cm) and median RT dose was 45 Gy. Median OS was 10 months (95% CI, 9-10 months). On MV analysis RT dose <30 Gy [HR, 2.38 (95% CI, 1.85-3.07); P<0.001] and RT dose ≥30 to <40 Gy [HR, 1.41 (95% CI, 1.04-1.91); P=0.026] were associated with lower OS when compared with dose ≥55 Gy. Patients receiving RT doses from 40 to <45, 45 to <50, 50 to <55, and ≥55 Gy did not differ in OS. CONCLUSIONS: Lack of benefit to OS with conventionally delivered RT above 40 Gy is shown. Optimal RT dose escalation methods in unresectable PAC remain an important subject for investigation in prospective clinical trials.
PURPOSE: Radiation therapy (RT) dose escalation in unresectable pancreatic adenocarcinoma (PAC) remains investigational. We examined the association between total RT dose and overall survival (OS) in patients with unresectable PAC. METHODS AND MATERIALS: National cancer data base (NCDB) data were obtained for patients who underwent definitive chemotherapy and RT (chemo-RT) for unresectable PAC. Univariate (UV) and multivariate (MV) survival analysis were performed along with Kaplan-Meier (KM) estimates for incremental RT dose levels. RESULTS: A total of 977 analyzable patients met inclusion criteria. Median tumor size was 4.0 cm (0.3-40 cm) and median RT dose was 45 Gy. Median OS was 10 months (95% CI, 9-10 months). On MV analysis RT dose <30 Gy [HR, 2.38 (95% CI, 1.85-3.07); P<0.001] and RT dose ≥30 to <40 Gy [HR, 1.41 (95% CI, 1.04-1.91); P=0.026] were associated with lower OS when compared with dose ≥55 Gy. Patients receiving RT doses from 40 to <45, 45 to <50, 50 to <55, and ≥55 Gy did not differ in OS. CONCLUSIONS: Lack of benefit to OS with conventionally delivered RT above 40 Gy is shown. Optimal RT dose escalation methods in unresectable PAC remain an important subject for investigation in prospective clinical trials.
Entities:
Keywords:
PAC and intensity modulated radiation therapy (IMRT); PAC and radiation therapy (RT); RT dose in unresectable pancreatic cancer; Radiation dose escalation pancreatic cancer; dose response pancreatic cancer; radiation dose escalation in pancreatic adenocarcinoma (PAC); unresectable pancreatic cancer
Authors: Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase Journal: Radiother Oncol Date: 2005-07 Impact factor: 6.280
Authors: William A Hall; John L Mikell; Pardeep Mittal; Lauren Colbert; Roshan S Prabhu; David A Kooby; Dana Nickleach; Krisztina Hanley; Juan M Sarmiento; Arif N Ali; Jerome C Landry Journal: Int J Radiat Oncol Biol Phys Date: 2013-01-03 Impact factor: 7.038
Authors: H M Ceha; G van Tienhoven; D J Gouma; C H Veenhof; C J Schneider; E A Rauws; S S Phoa; D González González Journal: Cancer Date: 2000-12-01 Impact factor: 6.860
Authors: Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-27 Impact factor: 7.038
Authors: C J McGinn; M M Zalupski; I Shureiqi; J M Robertson; F E Eckhauser; D C Smith; D Brown; G Hejna; M Strawderman; D Normolle; T S Lawrence Journal: J Clin Oncol Date: 2001-11-15 Impact factor: 44.544
Authors: Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff Journal: PLoS Med Date: 2010-04-20 Impact factor: 11.069
Authors: Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: Andrew H Ko; Jeanne M Quivey; Alan P Venook; Emily K Bergsland; Elizabeth Dito; Brian Schillinger; Margaret A Tempero Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-23 Impact factor: 7.038
Authors: Sung Jun Ma; Lucas M Serra; Austin J Bartl; Hye Ri Han; Fatemeh Fekrmandi; Austin J Iovoli; Kavitha M Prezzano; Gregory M Hermann; Han Yu; Anurag K Singh Journal: J Radiother Pract Date: 2021-04-14
Authors: Dalia Elganainy; Emma B Holliday; Cullen M Taniguchi; Grace L Smith; Rachna Shroff; Milind Javle; Kanwal Raghav; Ahmed Kaseb; Thomas A Aloia; Jean Nicolas Vauthey; Ching-Wei D Tzeng; Joseph M Herman; Albert C Koong; Sunil X Krishnan; Bruce D Minsky; Christopher H Crane; Prajnan Das; Eugene J Koay Journal: Cancer Med Date: 2018-08-27 Impact factor: 4.452
Authors: Yazheng Chen; Xinfeng Chen; William Hall; Phil Prior; Ying Zhang; Eric Paulson; Jinyi Lang; Beth Erickson; X Allen Li Journal: Phys Imaging Radiat Oncol Date: 2019-11-20